Compare GERN & SEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GERN | SEB |
|---|---|---|
| Founded | 1990 | 1918 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Farming/Seeds/Milling |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 4.3B |
| IPO Year | 1996 | 1994 |
| Metric | GERN | SEB |
|---|---|---|
| Price | $1.51 | $4,304.81 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $2.17 | N/A |
| AVG Volume (30 Days) | ★ 9.0M | 17.5K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | ★ 0.17% |
| EPS Growth | 51.85 | ★ 467.71 |
| EPS | N/A | ★ 283.99 |
| Revenue | $1,065,000.00 | ★ $5,809,000,000.00 |
| Revenue This Year | $26.91 | N/A |
| Revenue Next Year | $43.75 | N/A |
| P/E Ratio | ★ N/A | $15.22 |
| Revenue Growth | N/A | ★ 7.99 |
| 52 Week Low | $1.04 | $3,140.01 |
| 52 Week High | $2.01 | $5,989.37 |
| Indicator | GERN | SEB |
|---|---|---|
| Relative Strength Index (RSI) | 50.71 | 52.17 |
| Support Level | $1.43 | $4,287.18 |
| Resistance Level | $1.64 | $4,715.63 |
| Average True Range (ATR) | 0.08 | 154.93 |
| MACD | -0.00 | 37.89 |
| Stochastic Oscillator | 41.67 | 66.71 |
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
Seaboard Corp is a diversified group of companies that operate in agricultural, energy, and ocean transport businesses. The company is engaged in hog production, biofuel production, and pork processing in the United States; commodity trading and grain processing in Africa and South America; cargo shipping services in the U.S., Caribbean and Central and South America; sugar and alcohol production in Argentina; and electric power generation in the Dominican Republic. It also has an equity method investment in Butterball, LLC, a producer and processor of turkey products. The group's operating segments are; pork, commodity trading and milling, marine, liquid fuels, power, turkey, and others. It operates in 45 countries, with a concentration in the Caribbean, Central and South American region.